iCo Therapeutics Successfully Concludes Phase 1b Clinical Study Announces Positive Primary End Point for Oral Amphotericin B – Yahoo Finance

iCo Therapeutics Successfully Concludes Phase 1b Clinical Study Announces Positive Primary End Point for Oral Amphotericin B  Yahoo Finance